文献速递眼底病与葡萄膜炎眼整形与眼眶

钌-106 敷贴器近距离放射治疗虹膜黑色素瘤:苏格兰经验

Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
PubMed 文献 · Br J Ophthalmol · 2017-06-09

回顾性分析 1998–2016 年苏格兰眼科肿瘤服务中心 19 例纯虹膜黑色素瘤患者接受钌-106 敷贴器(置于角膜表面、表面剂量 555 Gy)治疗的结果:平均随访 62 个月时肿瘤控制率和保眼率均为 100%,超声显示肿瘤高度降低 62%,并发症包括白内障(68%)、干眼(47%)、葡萄膜炎(37%)和巩膜变薄(5%),末次随访时 53% 患者视力维持在 6/9 或更好,无有症状的转移或黑色素瘤相关死亡。

要点

  • 19 例纯虹膜黑色素瘤接受钌-106 敷贴器治疗,表面剂量 555 Gy,平均随访 62 个月。
  • 肿瘤控制率和保眼率均为 100%,超声显示肿瘤高度降低 62%。
  • 并发症包括白内障 68%、干眼 47%、葡萄膜炎 37%、巩膜变薄 5%。

核心结论

  • 钌-106 敷贴器治疗虹膜黑色素瘤高度有效,肿瘤控制率高、无肿瘤复发,并发症率相对较低。

研究设计与样本

  • 回顾性分析 1998 年至 2016 年苏格兰眼科肿瘤服务中心 19 例连续纯虹膜黑色素瘤患者的病历资料,均接受钌-106 敷贴器近距离放射治疗,敷贴器置于角膜表面、表面剂量 555 Gy。

主要发现

  • 病灶平均最大基底径 3.50±1.42 mm(范围 1.6–6.5 mm),平均最大高度 1.47±0.65 mm(范围 0.7–2.8 mm)。
  • 平均随访 62 个月(范围 6–195 个月)时,肿瘤控制率和保眼率均为 100%。
  • 超声显示肿瘤高度降低 62%。
  • 并发症包括白内障 68%、干眼 47%、葡萄膜炎 37%、巩膜变薄 5%。
  • 末次随访时平均 Snellen 视力下降 1.11±2.90 行,53% 患者视力维持在 6/9 或更好;无患者出现有症状的转移(未行影像学检查)或黑色素瘤相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyse long-term outcomes of ruthenium-106 (106Ru) plaque brachytherapy for the treatment of iris melanoma. METHODS: We retrospectively reviewed medical records of 19 consecutive patients with pure iris melanoma treated with 106Ru plaque brachytherapy between 1998 and 2016 at the Scottish Ophthalmic Oncology Service, Glasgow. The iris melanoma was treated with a ruthenium plaque placed on the corneal surface to deliver a surface dose of 555 Gy. We analysed vision preservation, local tumour control, radiation-related complications, eye retention rates, symptomatic metastasis and melanoma-related mortality. RESULTS: The mean largest basal diameter of the lesions was 3.50±1.42 mm (range 1.6-6.5 mm), and the mean maximum height was 1.47±0.65 mm (range 0.7-2.8 mm). The tumour control and eye retention were 100% at a mean follow-up of 62 months (range 6-195 months). A 62% reduction in tumour height was observed on ultrasonography. Complications included cataract (68%), dry eye (47%), uveitis (37%) and scleral thinning (5%). At the final follow-up visit, the mean loss of Snellen visual acuity was 1.11±2.90 lines and vision of 6/9 or better was maintained in 53% of patients. None of the patients had evidence of symptomatic metastasis (non-imaged) or melanoma-related mortality. CONCLUSIONS: 106Ru plaque treatment for iris melanoma was highly effective a high tumour control, no tumour recurrences and a relatively a low complication rate.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Agraval U, Sobti M, Russell HC, et al. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience. Br J Ophthalmol. 2017. PMID: 28600302. doi:10.1136/bjophthalmol-2017-310278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。